Kindeva Drug Delivery
Contract development and manufacturing organization (CDMO) focused on combination products for pulmonary, nasal, injectable and transdermal routes. Provides end-to-end services from formulation and device/platform development to clinical and commercial manufacturing, analytical testing, modeling and regulatory support. Operates multiple facilities in the U.S. and the U.K. and conducts R&D in aerosol performance, low‑GWP propellants, microneedle array patches, and device/platform engineering.
Industries
N/A
Nr. of Employees
medium (51-250)
Kindeva Drug Delivery
Patents
Products
Autoinjector device platforms
Configurable autoinjector device platforms designed for single‑use self‑administration with options for different volumes and chamber configurations suitable for prefilled syringes and cartridges.
Microneedle array patches
Solid‑coated and liquid/hollow microneedle arrays for intradermal delivery intended for vaccines and intradermal therapeutics, with characterization and scale‑up support.
Inhalation device platforms and support
Platform development and manufacturing support for a range of inhalation and nasal device types, including formulation, APSD testing, and support for propellant changes.
Autoinjector device platforms
Configurable autoinjector device platforms designed for single‑use self‑administration with options for different volumes and chamber configurations suitable for prefilled syringes and cartridges.
Microneedle array patches
Solid‑coated and liquid/hollow microneedle arrays for intradermal delivery intended for vaccines and intradermal therapeutics, with characterization and scale‑up support.
Inhalation device platforms and support
Platform development and manufacturing support for a range of inhalation and nasal device types, including formulation, APSD testing, and support for propellant changes.
Services
Integrated services covering device and product development, analytical testing, clinical supply and commercial manufacturing for pulmonary, nasal, injectable and transdermal products.
Analytical support across the product lifecycle including method development/validation, stability testing, extractables and leachables assessment, and elemental impurity analysis.
Device selection, formulation development, aerosol characterisation, propellant transition support and clinical/commercial manufacturing for pMDI, DPI, SMI, nebulizers and nasal sprays.
End‑to‑end transdermal patch and microneedle array patch development including formulation, coating/converting, applicator design, manufacturing and analytical support.
Technical, development and filling services to support transitions to low‑GWP propellants, including clinical supply, pilot filling and commercial scale filling capability.
Integrated services covering device and product development, analytical testing, clinical supply and commercial manufacturing for pulmonary, nasal, injectable and transdermal products.
Analytical support across the product lifecycle including method development/validation, stability testing, extractables and leachables assessment, and elemental impurity analysis.
Device selection, formulation development, aerosol characterisation, propellant transition support and clinical/commercial manufacturing for pMDI, DPI, SMI, nebulizers and nasal sprays.
End‑to‑end transdermal patch and microneedle array patch development including formulation, coating/converting, applicator design, manufacturing and analytical support.
Technical, development and filling services to support transitions to low‑GWP propellants, including clinical supply, pilot filling and commercial scale filling capability.
Expertise Areas
- Combination product device and platform development
- Sterile injectable fill‑finish and aseptic manufacturing
- Pulmonary and nasal drug delivery development
- Transdermal and intradermal (microneedle) delivery
Key Technologies
- Pressurized metered‑dose inhaler (pMDI) technology
- Dry powder inhaler (DPI) platforms
- Soft‑mist and nebulizer aerosol systems
- Nasal spray delivery systems
News & Updates
Completion of first registration batch on a high‑volume vial line at the Bridgeton, MO aseptic injectable fill‑finish facility, demonstrating facility readiness for commercial sterile production.
Business unit secured a contract valued up to $129 million to supply emergency responder autoinjectors to a national stockpile.
Launch of a UK site to expand metered‑dose inhaler services and develop/test next‑generation low‑GWP propellants.
Partnership announced to co‑develop an administration solution for circular RNA‑based vaccines.
Appointment of David Stevens as President to lead global operations.
Presentation on ensuring combination product compliance with regulatory requirements through analytical testing.
Completion of first registration batch on a high‑volume vial line at the Bridgeton, MO aseptic injectable fill‑finish facility, demonstrating facility readiness for commercial sterile production.
Business unit secured a contract valued up to $129 million to supply emergency responder autoinjectors to a national stockpile.
Launch of a UK site to expand metered‑dose inhaler services and develop/test next‑generation low‑GWP propellants.
Partnership announced to co‑develop an administration solution for circular RNA‑based vaccines.
Appointment of David Stevens as President to lead global operations.
Presentation on ensuring combination product compliance with regulatory requirements through analytical testing.